Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
341.12
-25.73 (-7.01%)
At close: Jul 31, 2026, 4:00 PM EDT
340.00
-1.12 (-0.33%)
After-hours: Jul 31, 2026, 7:40 PM EDT
Krystal Biotech Revenue
Krystal Biotech had revenue of $116.36M in the quarter ending March 31, 2026, with 31.95% growth. This brings the company's revenue in the last twelve months to $417.30M, up 25.15% year-over-year. In the year 2025, Krystal Biotech had annual revenue of $389.13M with 33.94% growth.
Revenue (ttm)
$417.30M
Revenue Growth
+25.15%
P/S Ratio
24.10
Revenue / Employee
$1,414,590
Employees
295
Market Cap
10.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 389.13M | 98.62M | 33.94% |
| Dec 31, 2024 | 290.52M | 239.82M | 473.02% |
| Dec 31, 2023 | 50.70M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.24B |
| Halozyme Therapeutics | 1.51B |
| Bio-Techne | 1.21B |
| Madrigal Pharmaceuticals | 1.13B |
| Corcept Therapeutics | 769.10M |
| Axsome Therapeutics | 708.24M |
| Arrowhead Pharmaceuticals | 622.01M |
| Cytokinetics | 105.82M |
KRYS News
- 8 days ago - Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026 - GlobeNewsWire
- 11 days ago - Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600 - PRNewsWire
- 11 days ago - Krystal Biotech to replace Taylor Morrison in S&P 400 at open on 7/24 - TheFly
- 11 days ago - Tutor Perini to replace Krystal Biotech in S&P 600 at open on 7/24 - TheFly
- 17 days ago - Krystal Biotech price target raised to $396 from $364 at BofA - TheFly
- 18 days ago - Krystal Biotech price target raised to $474 from $399 at Jefferies - TheFly
- 6 weeks ago - Krystal Biotech price target raised to $403 from $306 at TD Cowen - TheFly
- 6 weeks ago - Krystal Biotech price target raised to $361 from $310 at H.C. Wainwright - TheFly